Dan Teleman
CEO
|
Prior to joining Atox Bio, Mr. Teleman was the co-founder and CEO of PainReform, a specialty pharmaceutical company focused on pain therapeutics. Before founding PainReform in 2007, Mr. Teleman was a senior Business Development officer at Pharmos, a company focused on the R&D of novel CB2 receptor agonists for the treatment of neuropathic and inflammatory pain. Prior to Pharmos, Mr. Teleman held marketing and sales positions at Amgen, working on Enbrel. Dan served as an officer in an Israel Defense Forces R&D unit, holds an MBA from Duke University-Fuqua School of Business and an MSc in Biotechnology from Ben Gurion University.
|
Dr. Raymond Kaempfer
CSO
|
A molecular biologist, obtained his PhD at MIT and served on the biology faculty of Harvard University before becoming the Philip Marcus Professor of Molecular Biology and Cancer Research, Faculty of Medicine, The Hebrew University of Jerusalem. He is an elected member of the European Molecular Biology Organization and created the Graduate Program in Biotechnology of the Hebrew University.
|
Dr. Anat Shirvan
VP R&D
|
Before joining Atox Bio she was the co-founder, EVP R&D and director at Aposense Ltd. Dr. Shirvan led the drug development of Aposense technology from its conception, advancing it from discovery stage to pre-clinical and clinical development while overseeing all related regulatory aspects. Dr. Shirvan earned a PhD in molecular biology from The Hebrew University of Jerusalem, and did post-doctoral research for 4 years at NIH studying the annexin family of calcium-binding proteins.
|